CAPTRUST Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $643K | Buy |
20,412
+2,681
| +15% | +$84.5K | ﹤0.01% | 1583 |
|
2025
Q1 | $581K | Buy |
17,731
+337
| +2% | +$11K | ﹤0.01% | 1573 |
|
2024
Q4 | $629K | Buy |
17,394
+7,969
| +85% | +$288K | ﹤0.01% | 1491 |
|
2024
Q3 | $294K | Sell |
9,425
-819
| -8% | -$25.5K | ﹤0.01% | 1887 |
|
2024
Q2 | $274K | Sell |
10,244
-87
| -0.8% | -$2.33K | ﹤0.01% | 1862 |
|
2024
Q1 | $352K | Buy |
10,331
+1,474
| +17% | +$50.3K | ﹤0.01% | 1682 |
|
2023
Q4 | $256K | Sell |
8,857
-1,502
| -14% | -$43.5K | ﹤0.01% | 2218 |
|
2023
Q3 | $286K | Buy |
+10,359
| New | +$286K | ﹤0.01% | 2021 |
|
2023
Q2 | – | Sell |
-6,250
| Closed | -$226K | – | 2588 |
|
2023
Q1 | $226K | Buy |
6,250
+209
| +3% | +$7.57K | ﹤0.01% | 1966 |
|
2022
Q4 | $215K | Buy |
6,041
+127
| +2% | +$4.53K | ﹤0.01% | 1901 |
|
2022
Q3 | $200K | Buy |
5,914
+2,710
| +85% | +$91.6K | ﹤0.01% | 1823 |
|
2022
Q2 | $93K | Buy |
3,204
+221
| +7% | +$6.42K | ﹤0.01% | 2252 |
|
2022
Q1 | $96K | Buy |
2,983
+1,850
| +163% | +$59.5K | ﹤0.01% | 2309 |
|
2021
Q4 | $33K | Buy |
1,133
+91
| +9% | +$2.65K | ﹤0.01% | 2969 |
|
2021
Q3 | $28K | Buy |
1,042
+146
| +16% | +$3.92K | ﹤0.01% | 2949 |
|
2021
Q2 | $28K | Sell |
896
-20
| -2% | -$625 | ﹤0.01% | 2893 |
|
2021
Q1 | $24K | Buy |
916
+641
| +233% | +$16.8K | ﹤0.01% | 2897 |
|
2020
Q4 | $7K | Buy |
275
+50
| +22% | +$1.27K | ﹤0.01% | 2714 |
|
2020
Q3 | $5K | Buy |
225
+50
| +29% | +$1.11K | ﹤0.01% | 2543 |
|
2020
Q2 | $4K | Buy |
+175
| New | +$4K | ﹤0.01% | 2463 |
|
2019
Q4 | – | Sell |
-130
| Closed | -$4K | – | 1708 |
|
2019
Q3 | $4K | Hold |
130
| – | – | ﹤0.01% | 1697 |
|
2019
Q2 | $4K | Buy |
+130
| New | +$4K | ﹤0.01% | 1705 |
|
2018
Q3 | – | Sell |
-15
| Closed | -$1K | – | 1697 |
|
2018
Q2 | $1K | Buy |
+15
| New | +$1K | ﹤0.01% | 1469 |
|